GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (NAS:XNCR) » Definitions » Sloan Ratio %

XNCR (Xencor) Sloan Ratio % : -2.37% (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Xencor Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Xencor's Sloan Ratio for the quarter that ended in Dec. 2024 was -2.37%.

As of Dec. 2024, Xencor has a Sloan Ratio of -2.37%, indicating the company is in the safe zone and there is no funny business with accruals.


Xencor Sloan Ratio % Historical Data

The historical data trend for Xencor's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xencor Sloan Ratio % Chart

Xencor Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.39 17.39 4.73 5.79 -2.37

Xencor Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.79 9.64 0.19 19.24 -2.37

Competitive Comparison of Xencor's Sloan Ratio %

For the Biotechnology subindustry, Xencor's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xencor's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xencor's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Xencor's Sloan Ratio % falls into.


;
;

Xencor Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Xencor's Sloan Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2024 )-Cash Flow from Operations (A: Dec. 2024 )
-Cash Flow from Investing (A: Dec. 2024 ))/Total Assets (A: Dec. 2024 )
=(-232.618--202.188
--7.872)/951.945
=-2.37%

Xencor's Sloan Ratio for the quarter that ended in Dec. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2024 )
=(-232.618--202.188
--7.872)/951.945
=-2.37%

Xencor's Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was -73.44 (Mar. 2024 ) + -67.337 (Jun. 2024 ) + -46.288 (Sep. 2024 ) + -45.553 (Dec. 2024 ) = $-232.6 Mil.
Xencor's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2024 was -56.859 (Mar. 2024 ) + -67.35 (Jun. 2024 ) + -28.142 (Sep. 2024 ) + -49.837 (Dec. 2024 ) = $-202.2 Mil.
Xencor's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2024 was 32.318 (Mar. 2024 ) + 66.016 (Jun. 2024 ) + -163.458 (Sep. 2024 ) + 57.252 (Dec. 2024 ) = $-7.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xencor  (NAS:XNCR) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2024, Xencor has a Sloan Ratio of -2.37%, indicating the company is in the safe zone and there is no funny business with accruals.


Xencor Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Xencor's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xencor Business Description

Traded in Other Exchanges
Address
465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Executives
Nancy Valente director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Celia Eckert officer: VP, GENERAL COUNSEL C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John R Desjarlais officer: SR. VICE PRESIDENT & CSO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Bassil I Dahiyat director, officer: PRESIDENT & CEO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Alan Bruce Montgomery director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Richard J Ranieri director 3005 FIRST AVE, SEATTLE WA 98121
Ellen Feigal director C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Kevin Charles Gorman director 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Kurt A Gustafson director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
John J Kuch officer: SR. VICE PRESIDENT & CFO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Allen Yang officer: SR. VICE PRESIDENT & CMO C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Stafford John S Iii 10 percent owner 230 SOUTH LASALLE STREET 400, CHICAGO IL 60604